stockrow
Friday 6 November 2026
Export PLUR’s income statement to Excel — free account
Pluri Inc.
PLUR Healthcare Biotechnology
Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025.
- Revenue
- −15.8%
- EPS
- +44.8%
- Free cash flow
- +25.0%
- Total debt
- +3.43%
Quarter to June 2026, against a year earlier
1.24
0.05
+4.20%
Follow PLUR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | 0 | 0 | 0 | — | 0 | 0 | 0 | 1 | 1 | +45.7% | 10 | — | — | +902.0% | |
| Gross margin, % | 0.00 | 96.00 | 96.30 | 100.00 | 0.00 | 100.00 | 96.86 | 98.77 | 48.95 | 44.59 | +44.6 pt | ||||||
| EBT | (28) | (26) | (35) | (29) | (50) | (41) | (29) | (21) | (23) | (25) | (1.0%) | ||||||
| EBT margin, % | 0.00 | (52,252.00) | (65,383.33) | (126,747.83) | 0.00 | (17,681.20) | (10,065.16) | (6,547.24) | (1,740.64) | (2,499.41) | (2,499.4) pt | ||||||
| Net income | (28) | (26) | (35) | (29) | (50) | (41) | (29) | (21) | (23) | (25) | (1.0%) | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.04 | 0.04 | 0.01 | 0.00 | 0.06 | 0.06 | 0.06 | 0.21 | 0.10 | n/m | |||||
| Earnings | (25.60) | (20.00) | (21.36) | (12.37) | (14.16) | (10.24) | (6.24) | (3.99) | (3.56) | (2.44) | (23.0%) | ||||||
| Cash flow | (19.77) | (16.15) | (19.11) | (11.59) | (8.80) | (9.07) | (4.99) | (3.44) | (2.87) | (2.01) | (22.4%) | ||||||
| Capex | (0.32) | (0.26) | (0.15) | (0.12) | (0.11) | (0.07) | (0.06) | (0.06) | (0.26) | (0.06) | (16.5%) | ||||||
| Free cash flow | (20.09) | (16.41) | (19.26) | (11.71) | (8.90) | (9.14) | (5.05) | (3.50) | (3.13) | (2.07) | (22.3%) | ||||||
| Book value | 27.68 | 21.54 | 14.15 | 24.66 | 16.26 | 8.00 | 3.34 | 1.03 | (0.14) | (1.79) | n/m | ||||||
| Shares, m | 1 | 1 | 2 | 2 | 4 | 4 | 5 | 5 | 6 | 10 | +27.5% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | 45.69 | 699.65 | 2,089.09 | — | 128.98 | 102.50 | 92.58 | 23.48 | 20.04 | 400.3 | ||||||
| P/B | — | 4.64 | 3.33 | 2.87 | — | 1.23 | 1.92 | 5.57 | 0.00 | 0.00 | 2.4 | ||||||
| EV/Sales | — | 35.13 | 465.06 | 1,507.87 | — | 19.28 | 45.76 | 75.50 | 46.83 | 40.12 | 279.4 | ||||||
| EV/FCF | — | (4.68) | (1.63) | (4.36) | — | (0.16) | (0.57) | (1.34) | (3.16) | (2.02) | (2.2) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (22) | (21) | (29) | (26) | (31) | (37) | (23) | (18) | (18) | (20) | (1.1%) | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (2) | (1) | +6.5% | ||||||
| Free cash flow | (22) | (22) | (30) | (27) | (31) | (37) | (23) | (18) | (20) | (20) | (0.9%) | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 24 | 23 | 18 | 40 | 56 | 51 | 36 | 27 | (10) | (24) | n/m | |||||
| Net debt | (27) | (31) | (24) | (45) | (41) | (34) | (16) | (6) | 6 | 20 | n/m | ||||||
| Shareholders’ equity | 30 | 29 | 22 | 56 | 57 | 32 | 15 | 5 | (1) | (17) | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (66.64) | (68.31) | (100.49) | (60.21) | (62.70) | (51.04) | (47.65) | (46.25) | (57.75) | (74.95) | (8.3) pt | |||||
| ROIC | (488.34) | 0.00 | 0.00 | (162.36) | (196.66) | 0.00 | 0.00 | 0.00 | (257.19) | (526.92) | (38.6) pt | ||||||
| ROE | (81.32) | (88.93) | (140.31) | (74.82) | (88.06) | (92.33) | (119.28) | (201.67) | (992.66) | 260.35 | +341.7 pt | ||||||
| People | |||||||||||||||||
| People | Employees | 183 | 180 | 165 | 158 | 162 | 159 | 134 | 118 | 142 | 113 | (5.2%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026
Pluri Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $15.5M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.3M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| PLUR Pluri Inc. | $15.0M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| KYNB Kyntra Bio Inc | $14.8M | 0.1× | — (loss-making) | −209.35% (below 0%: shrinking) | n/m | −131.50% (below 0%: shrinking) | 100.14% | 1,192.27% | Compare |
| ATYR aTyr Pharma, Inc. | $14.8M | — (loss-making) | — (loss-making) | −90.75% (below 0%: shrinking) | n/m | +32.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| Median of peers | $15.0M | — | — | −95.49% | — | −23.96% | 90.86% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.50m | 577.09k | (489.00) |
| 2024 | 741.48k | 306.68k | (406.00) |
| 2023 | 2.63m | (238.00k) | (344.00) |
Ownership
Directors and executive officers, together
43.16%
Alexandre Weinstein Chairman of the Board of Directors
35.00%
Chutzpah Holdings LP
20.80%
Chutzpah Holdings Ltd.
18.60%
Merchant Adventure Fund L.P.
12.30%
Yaky Yanay CEO, President and Director
5.90%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement